Purpose: Most important factor affecting prognosis of breast cancer is axillary nodal involvement. Several studies evaluated the accuracy of Sentinel lymph node biopsy in breast cancer patients post neoadjuvant chemotherapy. In this study, we will examine accuracy and feasibility of using Sentinel lymph node biopsy in predicting axillary lymph node status in breast cancer patients after neoadjuvant chemotherapy. Methods: 45 female patients with resectable, nonmetastatic breast carcinoma cases who received neoadjuvant chemotherapy were enrolled in this study according to the routine Mansoura Oncology Center—guidelines of management of breast cancer. Methylene blue dye used for detection of Sentinel lymph node. Results: Successful Sentinel lymph node detection was 82.2%. Skin involvement (T4 disease) were linked to a low identification (P = 0.005). False negative rate equals 11/27 = (40.7%).With advancement of the stage of the tumor, the incidence of false negative results increases significantly (p = 0.012) with 95% confidence interval; 1.2 - 5.4. Conclusion: Sentinel lymph node should be adopted to be the standard method for axillary staging with T1-3 tumors after receiving neoadjuvant chemotherapy, in T4 patients, it is associated with low detection rate & high false negative rate making it doubtful technique for axillary staging.
References
[1]
Gherghe, M., Bordea, C. and Blidaru, A. (2014) Sentinel Lymph Node Biopsy (SLNB) vs. Axillary Lymph Node Dissection (ALND) in the Current Surgical Treatment of Early Stage Breast Cancer. Journal of Medicine and Life, 8, 176-180.
[2]
Khavanin, N., Gart, M.S., Berry, T., Thornton, B., Saha, S. and Kim, J.Y. (2014) Sentinel Lymph Node Biopsy versus Axillary Lymphadenectomy in Patients Treated with Lumpectomy: An Analysis of Short-Term Outcomes. Annals of Surgical Oncology, 21, 74-80. https://doi.org/10.1245/s10434-013-3248-3
[3]
Tsujimoto, M. (2015) Recent Advances in Sentinel Node Biopsy in Breast Surgery. Breast Cancer, 22, 211. https://doi.org/10.1007/s12282-015-0601-3
[4]
Holmes, D., Colfry, A., Czerniecki, B., Dickson-Witmer, D., Espinel, C. F., Feldman, E. and Kuerer, H. (2015) Performance and Practice Guideline for the Use of Neoadjuvant Systemic Therapy in the Management of Breast Cancer. Annals of Surgical Oncology, 22, 3184-3190. https://doi.org/10.1245/s10434-015-4753-3
[5]
Mamounas, E.P. (2015) Impact of Neoadjuvant Chemotherapy on Locoregional Surgical Treatment of Breast Cancer. Annals of Surgical Oncology, 22, 1425-1433.
https://doi.org/10.1245/s10434-015-4406-6
[6]
Benson, J.R. and Jatoi, I. (2014) Sentinel Lymph Node Biopsy and Neoadjuvant Chemotherapy in Breast Cancer Patients. Future Oncology, 10, 577-586.
https://doi.org/10.2217/fon.13.231
[7]
Yagata, H., Yamauchi, H., Tsugawa, K., Hayashi, N., Yoshida, A., Kajiura, Y. and Nakamura, S. (2013) Sentinel Node Biopsy after Neoadjuvant Chemotherapy in Cytologically Proven Node-Positive Breast Cancer. Clinical Breast Cancer, 13, 471-477. https://doi.org/10.1016/j.clbc.2013.08.014
[8]
Srivastava, A. and Misra, M. (2012) In Search of a Cost-Effective Sentinel Node Biopsy Technique: A Randomized Trial Comparing the Use of Methylene Blue and Patent Blue Violet to Identify Sentinel Node in Breast Cancer. Cancer Research, 72, 2705-2705. https://doi.org/10.1158/1538-7445.AM2012-2705
[9]
Giuliano, A.E., Kirgan, D.M., Guenther, J.M. and Morton, D.L. (1994) Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. Annals of Surgery, 220, 391. https://doi.org/10.1097/00000658-199409000-00015
[10]
Krag, D., Weaver, D., Alex, J., Fairbank, J., et al. (1993) Surgical Resection and Radiolocalization of the Sentinel Lymph Node in Breast Cancer Using a Gamma Probe. Surgical Oncology, 2, 335-340.
https://doi.org/10.1016/0960-7404(93)90064-6
[11]
Motomura, K. (2015) Sentinel Node Biopsy for Breast Cancer: Past, Present, and Future. Breast Cancer, 22, 212-220. https://doi.org/10.1007/s12282-012-0421-7
[12]
Varghese, P., Mostafa, A., Abdel-Rahman, A., Akberali, S., Gattuso, J., Canizales, A. and Carpenter, R. (2007) Methylene Blue Dye versus Combined Dye-Radioactive Tracer Technique for Sentinel Lymph Node Localisation in Early Breast Cancer. European Journal of Surgical Oncology (EJSO), 33, 147-152.
https://doi.org/10.1016/j.ejso.2006.09.026
[13]
Schwartz, G.F. and Meltzer, A.J. (2003) Accuracy of Axillary Sentinel Lymph Node Biopsy Following Neoadjuvant (Induction) Chemotherapy for Carcinoma of the Breast. The Breast Journal, 9, 374-379.
https://doi.org/10.1046/j.1524-4741.2003.09502.x
[14]
Xing, Y., Foy, M., Cox, D., Kuerer, H., Hunt, K. and Cormier, J. (2006) Meta-Analysis of Sentinel Lymph Node Biopsy after Preoperative Chemotherapy in Patients with Breast Cancer. British Journal of Surgery, 93, 539-546.
https://doi.org/10.1002/bjs.5209
[15]
Kelly, A.M., Dwamena, B., Cronin, P. and Carlos, R.C. (2009) Breast Cancer: Sentinel Node Identification and Classification after Neoadjuvant Chemotherapy—Systematic Review and Meta Analysis. Academic radiology, 16, 551-563.
https://doi.org/10.1016/j.acra.2009.01.026
[16]
van Deurzen, C.H., Vriens, B.E., Tjan-Heijnen, V.C., van der Wall, E., Albregts, M., van Hilligersberg, R. and Diest, P.J. (2009) Accuracy of Sentinel Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients: A Systematic Review. European Journal of Cancer, 45, 3124-3130.
https://doi.org/10.1016/j.ejca.2009.08.001
[17]
Kuehn, T., Bauerfeind, I., Fehm, T., Fleige, B., Helms, G., Lebeau, A. and Schrenk, P. (2012) Abstract S2-2: Sentinel Lymph Node Biopsy Before or after Neoadjuvant Chemotherapy—Final Results from the Prospective German, Multiinstitutional SENTINA-Trial. Cancer Research, 72, S2-2-S2-2.
https://doi.org/10.1158/0008-5472.SABCS12-S2-2
[18]
Tsuyuki, S., Yamaguchi, A., Kawata, Y. and Kawaguchi, K. (2015) Assessing the Effects of Neoadjuvant Chemotherapy on Lymphatic Pathways to Sentinel Lymph Nodes in Cases of Breast Cancer: Usefulness of the Indocyanine Green-Fluorescence Method. The Breast, 24, 298-301.
https://doi.org/10.1016/j.breast.2015.02.034
[19]
Nason, K.S., Anderson, B.O., Byrd, D.R., Dunnwald, L.K., Eary, J.F., Mankoff, D.A. and Yeung, R.S. (2000) Increased False Negative Sentinel Node Biopsy Rates after Preoperative Chemotherapy for Invasive Breast Carcinoma. Cancer, 89, 2187-2194.
[20]
Breslin, T.M., Cohen, L., Sahin, A., Fleming, J.B., Kuerer, H.M., Newman, L.A. and Feig, B.W. (2000) Sentinel Lymph Node Biopsy Is Accurate after Neoadjuvant Chemotherapy for Breast Cancer. Journal of Clinical Oncology, 18, 3480-3486.
https://doi.org/10.1200/JCO.2000.18.20.3480
[21]
Stearns, V., Ewing, C.A., Slack, R., Penannen, M.F., Hayes, D.F. and Tsangaris, T.N. (2002) Sentinel Lymphadenectomy after Neoadjuvant Chemotherapy for Breast Cancer May Reliably Represent the Axilla except for Inflammatory Breast Cancer. Annals of surgical oncology, 9, 235-242. https://doi.org/10.1007/BF02573060
[22]
Kwon, S., Agollah, G., Wu, G. and Sevick-Muraca, E.M. (2015) Abstract P5-01-04: In vivo Lymphatic Imaging of a Human Inflammatory Breast Cancer Model. Cancer Research, 75, P5-01-04. https://doi.org/10.1158/1538-7445.SABCS14-P5-01-04
[23]
Mocellin, S., Goldin, E., Marchet, A. and Nitti, D. (2015) Sentinel Node Biopsy Performance after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer: A Systematic Review and Meta-Analysis. International Journal of Cancer, 138, 472-480.
https://doi.org/10.1002/ijc.29644
[24]
Wang, Y., Dong, H., Wu, H., Zhang, L., Yuan, K., Chen, H. and Fu, R. (2015) Improved False Negative Rate of Axillary Status Using Sentinel Lymph Node Biopsy and Ultrasound-Suspicious Lymph Node Sampling in Patients with Early Breast Cancer. BMC Cancer, 15, 382. https://doi.org/10.1186/s12885-015-1331-9
[25]
Sekhar, G.C., Vamseedhar, K. and Babu, M.H. (2015) A Study of Sentinel Lymph Node Biopsy in Early Breast Cancer Using Methylene Blue in a Tertiary Care Hospital in South India. IOSR Journal of Dental and Medical Sciences (IOSR-JDMS), Dr. NTR University of Health Sciences, Vijayawada.
[26]
Boughey, J.C., Suman, V.J., Mittendorf, E.A., Ahrendt, G.M., Wilke, L.G., Taback, B. and Bowling, M. (2015) Factors Affecting Sentinel Lymph Node Identification Rate after Neoadjuvant Chemotherapy for Breast Cancer Patients Enrolled in ACOSOG Z1071 (Alliance). Annals of Surgery, 261, 547-552.
https://doi.org/10.1097/SLA.0000000000000551
[27]
Boughey, J.C., Suman, V.J., Mittendorf, E.A., Ahrendt, G.M., Wilke, L.G., Taback, B. and Flippo-Morton, T.S. (2013) Sentinel Lymph Node Surgery after Neoadjuvant Chemotherapy in Patients with Node-Positive Breast Cancer: The ACOSOG Z1071 (Alliance) Clinical Trial. JAMA, 310, 1455-1461.
https://doi.org/10.1001/jama.2013.278932
[28]
Tjan-Heijnen, V.C., Vriens, B.E., Aarts, M.J., Kroep, J.R., van de Velde, C.J., Liefers, G.-J. and de Boer, M. (2015) Abstract P2-01-03: Sentinel Node Procedure before or after Neoadjuvant Chemotherapy in Clinically Node Negative or Positive Patients; Results from 3 Phase III Studies of the Dutch Breast Cancer Trialists’ Group (BOOG). Cancer Research, 75, P2-01-03.
https://doi.org/10.1158/1538-7445.SABCS14-P2-01-03
